Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Sikov

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|November 20, 2009
Primary systemic amyloidosis and persistent pleural effusionsDan Schwarz, Christopher Jue, William Sikov
Breast Cancer Research and Treatment|May 21, 2008
'Weighing in' on screening mammographyDavid Berz, William Sikov, Gerald Colvin, et al.
Cancer|October 31, 2002
A phase I study of a weekly schedule of paclitaxel and carboplatin in patients with advanced carcinomaWallace Akerley, Ritesh Rathore, Neil Ready, et al.
Breast Cancer Research and Treatment|January 29, 2013
Effects of adjuvant chemotherapy in HER2-positive or triple-negative pT1ab breast cancers: a multi-institutional retrospective studyAdam J Olszewski, Yazan Migdady, Susan K Boolbol, et al.
BMC Cancer|June 3, 2014
Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumabHuan Cheng, Yalai Bai, William Sikov, et al.
American Journal of Clinical Oncology|November 7, 2014
Complete Neoadjuvant Treatment for Rectal Cancer: The Brown University Oncology Group CONTRE StudyKimberly Perez, Howard Safran, William Sikov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2016
Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast CancerVinay Varadan, Hannah Gilmore, Kristy L S Miskimen, et al.
International Journal of Radiation Oncology, Biology, Physics|October 16, 2010
Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancerTom Dipetrillo, Victor Pricolo, Jorge Lagares-Garcia, et al.
Journal of the National Cancer Institute|June 27, 2015
Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance)Jennifer A Ligibel, Constance T Cirrincione, Minetta Liu, et al.
International Journal of Cancer|August 19, 2015
Brief-exposure to preoperative bevacizumab reveals a TGF-β signature predictive of response in HER2-negative breast cancersVinay Varadan, Sitharthan Kamalakaran, Hannah Gilmore, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|November 20, 2009
Primary systemic amyloidosis and persistent pleural effusionsDan Schwarz, Christopher Jue, William Sikov
Breast Cancer Research and Treatment|May 21, 2008
'Weighing in' on screening mammographyDavid Berz, William Sikov, Gerald Colvin, et al.
Cancer|October 31, 2002
A phase I study of a weekly schedule of paclitaxel and carboplatin in patients with advanced carcinomaWallace Akerley, Ritesh Rathore, Neil Ready, et al.
Breast Cancer Research and Treatment|January 29, 2013
Effects of adjuvant chemotherapy in HER2-positive or triple-negative pT1ab breast cancers: a multi-institutional retrospective studyAdam J Olszewski, Yazan Migdady, Susan K Boolbol, et al.
BMC Cancer|June 3, 2014
Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumabHuan Cheng, Yalai Bai, William Sikov, et al.
American Journal of Clinical Oncology|November 7, 2014
Complete Neoadjuvant Treatment for Rectal Cancer: The Brown University Oncology Group CONTRE StudyKimberly Perez, Howard Safran, William Sikov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2016
Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast CancerVinay Varadan, Hannah Gilmore, Kristy L S Miskimen, et al.
International Journal of Radiation Oncology, Biology, Physics|October 16, 2010
Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancerTom Dipetrillo, Victor Pricolo, Jorge Lagares-Garcia, et al.
Journal of the National Cancer Institute|June 27, 2015
Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance)Jennifer A Ligibel, Constance T Cirrincione, Minetta Liu, et al.
International Journal of Cancer|August 19, 2015
Brief-exposure to preoperative bevacizumab reveals a TGF-β signature predictive of response in HER2-negative breast cancersVinay Varadan, Sitharthan Kamalakaran, Hannah Gilmore, et al.
Pageof 2